Compare Intikeramik Alamasri Industri Tbk. (IKAI) vs Brigit Biofarmaka Teknologi Tbk. (OBAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intikeramik Alamasri Industri Tbk. vs Brigit Biofarmaka Teknologi Tbk. — how do they compare? Intikeramik Alamasri Industri Tbk. trades at Rp19 (market cap 266.12B, 29.28M 24h volume), while Brigit Biofarmaka Teknologi Tbk. trades at Rp248 (market cap 167.37B, 74.8K 24h volume). The key difference: Intikeramik Alamasri Industri Tbk. is the larger of the two by market cap, and Intikeramik Alamasri Industri Tbk. is more actively traded (29.28M versus 74.8K). Which is the better fit depends on your goals.
| IKAI | OBAT | |
|---|---|---|
Market Cap | 266.12B | 167.37B |
Volume | 29.28M | 74.8K |
Lot | 292.83K | 748 |
Turnover | 571.61M | 18.41M |
Average Price | 19.52 | 246.12 |
Value | 571.61M | 18.41M |
Indicative Equilibrium Price | 19 | 246 |
Indicative Equilibrium Volume | 32.85K | 2.4K |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intikeramik Alamasri Industri Tbk.
PT Intikeramik Alamasri Industri Tbk (the Company) was established under the name PT Intikeramik Alamasri Indah based on notarial deed No. 38 dated June 26, 1991 and was amended with notarial deed No. 16 dated December 14, 1991, both made by Raden Muhammad Hendarmawan, S.H., Notary in Jakarta. PT Intikeramik Alamasri Industri Tbk is the pioneer of large-scale porcelain tile manufacture in Indonesia and one of the largest producers in the Asia Pacific region. Porcelain tiles are superior in term of strength, durability and design versatility to natural stone as well as other synthetics such as glazed tiles. Porcelain is attractive and affordable for use in both commercial and residential developments and has strong following among international architects and interior designers. Intikeramik is seeking to build a leading profile in markets across Europe, America and Asia drawing upon its reputation for consistency, advanced manufacturing technology, a low cost base and substantial available capacity. The company has consolidation production capacity 6,600,000 m2 /year.
Read more on IKAI →About Brigit Biofarmaka Teknologi Tbk.
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →
